Dr. Saro H. Armenian is the Barron Hilton Chair and Professor of Pediatrics and Director of the Division of Outcomes Research in the Department of Population Sciences at City of Hope. A Leukemia & Lymphoma Society Scholar, he leads NIH-funded research focused on the mechanisms, risk prediction, and prevention of cardiovascular disease in cancer survivors.

Dr. Lynda Balneaves is a Full Professor and Associate Dean, Research in the College of Nursing, University of Manitoba. Her research focuses on the use of complementary therapies by individuals with cancer. She is past president of the Society for Integrative Oncology.  

Otis W. Brawley, M.D., is the Bloomberg Distinguished Professor of Oncology and Epidemiology at Johns Hopkins University. He is an authority on cancer screening and prevention and leads a broad interdisciplinary research effort focused on cancer health disparities at the Johns Hopkins School of Medicine, the Bloomberg School of Public Health, and the Sidney Kimmel Comprehensive Cancer Center. Brawley is a Fellow of the Royal College of Physicians (London), a Fellow of the American Society of Clinical Oncology, a Fellow of the American College of Epidemiology and one of the few physicians to be named a Master of the American College of Physicians. He is an elected member of the National Academy of Medicine. Dr. Brawley is a graduate of University of Chicago Pritzker School of Medicine. He completed an internal medicine residency at Case-Western Reserve University and a fellowship in medical oncology at the National Cancer Institute. He is board certified in Internal medicine and medical oncology.

Dr. Carson is a Program Leader for the Health Outcomes and Behavior Research Program and an Associate Member in the Department of Health Outcomes and Behavior at Moffitt Cancer Center in Tampa, FL. She is a Moffitt Distinguished Scholar and the inaugural George Edgecomb Endowed Scholar. She completed her Bachelor’s degree in Biology at Florida State University. She received her Master’s degree and Ph.D. in Epidemiology from the University of Alabama at Birmingham and completed a post-doctoral fellowship at the University of Arkansas for Medical Sciences.  As an applied epidemiologist, Dr. Carson has made significant contributions to the field of obesity treatment and cancer risk reduction research through her population-based, bio-behavioral observational and intervention studies. Dr. Carson is currently the PI of 2 NIH-funded R01 studies investigating behavioral and biological aspects of energy balance, cancer prevention, and health disparities. She also serves as a co-investigator on Team SAMBAI, a Cancer Grand Challenges team examining cancer outcomes in a global context. In addition to a robust research program, Dr. Carson is dedicated to mentoring with an extensive track record of providing mentorship at levels ranging from undergraduate to junior faculty.

Professor Alexandre Chan is a Founding Chair and Professor of Clinical Pharmacy at the University of California, Irvine (UCI) School of Pharmacy & Pharmaceutical Sciences. He is a Visiting Professor at the National Cancer Center Singapore, Adjunct Faculty at Duke-NUS, and a Clinical Pharmacist at the Chao Family Comprehensive Cancer Center in Irvine, USA. A board-certified specialist in Pharmacotherapy and Oncology Pharmacy, Alex has published >330 peer-reviewed manuscripts in a wide array of cancer-supportive care and survivorship topics in medical and pharmacy journals, and his research program has attracted >10 million USD competitive funding support from various governmental agencies (NIH in the USA, NMRC in Singapore), foundations, and pharmaceutical companies. Alex is an elected Fellow of the American College of Clinical Pharmacy and the International Society of Oncology Pharmacy Practitioners (ISOPP), and a member of the Board of Pharmacy Specialties (BPS) Oncology Pharmacy Specialty Council. He was a Past President of ISOPP, and he is the President-Elect of the Multinational Association of Supportive Care in Cancer (MASCC) from 2024-2026, and President of MASCC from 2026-2028.

Dr. Susan Chang is a Professor in the Division of NeuroOncology and specializes in treating adults with brain tumors. She is a co-leader for the NeuroOncology Program for the Helen Diller Family Comprehensive Cancer Center and a Principal Investigator in the Brain Tumor Center. She has a major research focus on the development of novel therapies for patients and has served as the PI on numerous clinical trials. She is a leader on multi-programmatic grants (including NIH funded SPORE and Program Project Grants) that address the integration of physiologic and metabolic imaging with genomic biomarkers to optimize the management of patients with primary brain tumors. She is also a co-leader for a grant that addresses the interplay of genomic and immune characteristics with external factors that affect health outcomes in patients with meningioma, prostate and breast cancer. Dr. Chang is especially dedicated to improving the experience of her patients and their families, with a particular focus on increasing quality of life. She is the founder, Co-Director and Endowed Professor of the UCSF Neuro-Oncology Gordon Murray Caregiver Program, which provides resources and support to the caregivers of brain tumor patients. She is also the co-Director of the Sheri Sobrato Brain Cancer Survivorship Program focused on comprehensive survivorship care for brain tumor patients.

Dr. Susan Dent completed her medical degree at McMaster University in Hamilton, Ontario, followed by residency training in Internal Medicine and Medical Oncology at The Ottawa Hospital, University of Ottawa, and a postgraduate research fellowship in clinical trials with the Canadian Cancer Trials Group in Kingston, Ontario, before serving as staff medical oncologist in Thunder Bay. She returned to Ottawa in 2001 to specialize in breast cancer with a focus on new drug development, and in 2008 established a multidisciplinary cardio-oncology clinic, later founding the Canadian Cardiac Oncology Network in 2011 and launching the Global Cardio-Oncology Summit in 2015, now attended by clinicians from over 23 countries. From 2018 to 2024, Dr. Dent held a staff position at Duke University as Associate Director of Breast Cancer Clinical Research and Co-Director of the Duke Cardio-Oncology Program. Internationally recognized as a global leader in cardio-oncology, her work centers on evaluating novel breast cancer therapies while advancing understanding of their cardiovascular effects, and she has collaborated extensively with major global oncology and cardiology organizations. She is the Immediate Past President of the International Cardio-Oncology Society and, as of September 2024, holds a staff position at the University of Rochester as a breast cancer medical oncologist, Director of Cardio-Oncology, and Director of Survivorship at the Wilmot Cancer Institute.

Verlycia Dixon transitioned from being a medical assistant of 3 years to CHW in 2017. This change was birthed out of a passion for helping people and working in the community propelling her into doing community work full time at Henry Ford Health. As a CHW she has the pleasure of helping patients move past barriers that will prevent getting needed care for physical recovery.  She does this by forming relationships with patients that extend outside of the Henry Ford Health System. She is involved in several committees that are centered around diversity, equity, inclusion and justice as it is important to her that all persons, regardless of color, gender, age, sexual orientation, be treated equally within the health system.

Dr. Heather Greenlee is a cancer epidemiologist and a naturopathic physician.  She is a Professor in the Public Health Sciences and Clinical Research Divisions at the Fred Hutchinson Cancer Center and is the Medical Director of the Integrative Medicine Program.  She is also a Professor in the Division of Hematology and Oncology at the University of Washington School of Medicine and is an Adjunct Professor in the Department of Epidemiology at the University of Washington School of Public Health. Dr. Greenlee’s research focuses on the use of lifestyle modifications and complementary and integrative therapies for cancer prevention and survivorship, especially in populations underrepresented in research.  She uses observational studies and clinical trials to study what cancer survivors can do, in addition to conventional treatment, to prevent cancer recurrence, decrease side effects of treatment, and improve prognosis.  Dr. Greenlee is an active member of SWOG within the National Cancer Institute’s National Cancer Clinical Trials Network and is Past President of the Society for Integrative Oncology.  Her work is funded by the National Cancer Institute and she is an inaugural recipient of the Washington State Cancer Research Distinguished Researcher Grant.

Theresa Hastert, PhD, is an Associate Professor in the Department of Oncology at the Wayne State University School of Medicine and a Scientific Member of the Population Studies Program at the Karmanos Cancer Institute. Trained as an epidemiologist, Dr. Hastert’s research interests include the social, economic, and behavioral determinants of cancer outcomes, with a particular emphasis on racial and socioeconomic health disparities. Much of her work focuses on cancer survivorship, survivors’ and caregivers’ experiences of financial hardship and social risks, and their associations with quality of life and mortality. Her work is increasingly grounded in community engagement and long-standing collaborations with community partners. She is funded by the National Cancer Institute and the American Cancer Society, and her current projects include adapting an existing psychoeducational intervention for LGBTQ+ cancer survivors and caregivers, and developing a digital curriculum paired with digital support resources to help cancer survivors prevent and mitigate financial hardship.

Nofisat Ismaila, PhD, is a Senior Clinical Guideline Specialist at the American Society of Clinical Oncology (ASCO) with over 12 years of experience in health research methodology and guideline development. In her role, she supports multidisciplinary Expert Panels in the creation of evidence-based clinical practice guidelines and the transition of high-priority topics into the Living Guideline model. Dr. Ismaila plays a pivotal role in maintaining rigorous GRADE methodology standards and structured data processes that ensure ASCO’s recommendations are transparent, implementable, and current. Her recent work focuses on how these robust methodological frameworks, including the integration of AI and automated tools into the guideline development cycle, serve as the essential foundation for AI-driven dissemination and clinical decision-support tools.

A/Prof Judith Lacey is Head of Supportive Care and Integrative Oncology at Chris O’Brien Lifehouse in Sydney, a MASCC-designated Centre of Excellence. She is a national and  international leader in supportive cancer care and integrative oncology, focused on improving outcomes and quality of life. Judith holds adjunct appointments at the University of Sydney and NICM Health Research Institute, Western Sydney university, and is the Australian Ambassador Board member and fellow of the Society for Integrative Oncology. She chairs the MASCC Lifestyle and Integrative Medicine Study Group. Her research and work focuses on the integration of exercise oncology, integrative therapies, lymphoedema care, lifestyle medicine, medicinal cannabis, and PROMs, with research spanning implementation science, prehabilitation, survivorship, and service development.

Dr. Movsas is a nationally recognized expert in the field of radiation oncology, stereotactic radiosurgery, lung cancer, prostate cancer, and quality of life issues pertaining to cancer. He has published extensively in many prestigious medical journals and regularly presents his research findings at some of the nation’s top medical meetings. Dr. Movsas has been a leader in the most prominent academic organizations, including as President of the American Society for Radiation Oncology (ASTRO) Society of Chairs of Academic Radiation Oncology Programs (SCAROP), and President of the American Radium Society (ARS). He serves as the Chair of the National Cancer Institute (NCI) Patient Centered Outcomes Committee (PCOR) of the NRG cooperative group. He is recognized as a Fellow of the American Society of Radiation Oncology (ASTRO), the American College of Radiology (ACR), and the American Radium Society (ARS). He has also served as Chair of the Education Council on the ASTRO Board of Directors.

Margaret Raber is an Assistant Professor in the Department of Health Disparities Research at the University of Texas MD Anderson Cancer Center. Dr. Raber’s research, teaching and community service activities focus on practical nutrition education and food insecurity mitigation in cancer prevention and survivorship. She earned her Diplôme de Cuisine (culinary degree) from Le Cordon Bleu London in 2007, Bachelor of Science in Nutrition/Food Studies from New York University in 2010, Master of Public Health in 2014 and Doctorate of Public Health in Community Health Practice from the University of Texas School of Public Health in 2019. Dr. Raber’s research focuses on food is medicine approaches to cancer prevention and control. Specifically, her work aims to: 1)) identify relationships linking the home food environment, food security, diet and health, 2) build and test food security and nutrition education interventions for medically underserved populations and 3) expand culinary medicine approaches in medical school and community environments. Currently, Dr. Raber is PI of a USDA-funded project promoting healthy eating through culinary medicine and positive food parenting practices among families with low-income, as well as an American Cancer Society Research Scholar Grant examining a digital culinary medicine intervention to promote diet quality among cancer patients treated in a safety net oncology setting.  

Dr. Kathryn Schmitz is Deputy Director of the UPMC Hillman Cancer Center, a Professor of Hematology Oncology at the University of Pittsburgh School of Medicine and Former President of the American College of Sports Medicine.  As an international thought leader in exercise oncology, she is the founding president of the International Society of Exercise Oncology, which will have its inaugural meeting in July 2026.  She is also the Founder and Director of ACSM’s Moving Through Cancer initiative, which arose from the Exercise Is Medicine Initiative. She is first author of the first ACSM guidelines for exercise and cancer and senior author on the second ACSM guidelines for exercise and cancer. Dr. Schmitz is fellow of ACSM, TOS, NAK, and SBM and winner of numerous awards, including the President’s Council on Sports, Fitness, and Nutrition Lifetime Impact Award. 

Jessica Scott received her PhD from the University of British Columbia, where she studied the effects of prolonged endurance exercise on cardiac function in athletes and heart transplantation recipients. She completed a postdoctoral fellowship at NASA Johnson Space Center and then spent five years as a Senior Scientist in the Exercise Physiology and Countermeasures Laboratory, optimizing exercise training for astronauts on long-duration spaceflight missions. Her current research applies digital tools to characterize cancer therapy-related side effects and to deliver exercise interventions to mitigate treatment toxicities. At NASA, she received the Human Research Program Peer Award, the Innovation Achievement Award, and the Group Achievement Award as a member of the One Year Mission Operations Team.

Vic Strecher (pronounced ‘STREKER’) is a visionary leader and expert in the fields of behavior change, digital communication, and wellbeing. His pioneering research led to successful ventures, reaching millions of lives. He’s Professor at the University of Michigan School of Public Health, Founder & CEO of Kumanu, a next generation wellbeing company, and renowned researcher, educator, speaker, and author. In 1995, Vic founded the UM Center for Health Communications Research, studying the future of digitally-tailored health communications when fewer than 15% of Americans had Internet access. In 1997, he founded HealthMedia, a digital health coaching company that reached over 55 million people and was sold to Johnson & Johnson in 2010. More recently, Vic created Kumanu, a digital wellbeing platform designed to help individuals live more intentionally and purposefully. Vic and the organizations he founded have won numerous national and international awards, including two Smithsonian Awards, the Health Evolution Partners Innovations in Healthcare Award, and the National Business Coalition on Health’s Mercury Award. In 2010, he was named the Innovator of the Year at the University of Michigan while additionally recognized for Excellence in Translating Research into Practice. Vic also served as the only behavioral scientist on the National Cancer Institute’s Scientific Advisory Board under the Chairmanship of Nobel Laureate Harold Varmus. His 2009 TedMed presentation has been cited by MPHonline as one of the “Top 10 Ted Talks on Public Health.” In 2020 his free massive open online course Finding Purpose and Meaning in Life was rated the 4^th best online course in the world by Inc. Magazine and currently has over a quarter-million enrollees. His behavioral, neuroscience, and epigenetic research; two books (Life On Purpose and the graphic novel On Purpose); four Ted talks; two massive open online courses; and his Purposeful smartphone and web application are all focused on the importance of developing and maintaining strong core values, intentionality, and purpose in life.

Associate Professor Hannah Wardill, PhD, is an NHMRC Research Fellow and Principal Investigator leading the Supportive Oncology Research Group at the University of Adelaide and South Australia’s flagship medical research institute, SAHMRI. Her work integrates microbiome science, immunology, neuroscience and oncology to better understand and tackle the complex symptoms experienced by people with cancer. A/Prof Wardill has published more than 120 peer-reviewed papers, including in leading oncology journals such as the Journal of Clinical Oncology, with her work informing clinical trials and international clinical practice guidelines. She has attracted more than $15 million in competitive research funding from diverse sources, supporting a dynamic research program that spans fundamental and in vitro models through to co-designed clinical trials and implementation studies. A/Prof Wardill has been an active member of the Multinational Association of Supportive Care in Cancer (MASCC)for more than 12 years and has recently completed her second term on the MASCC Board of Directors. She previously led MASCC’s Patient Partnership Committee, is Vice-Chair of the Mucositis Study Group, and serves on the MASCC Research Committee. In recognition of her contributions, she was awarded MASCC Outstanding Educator and Outstanding Study Group Leader in 2025. In recognition of her expertise and impact, Hannah was a finalist in the 2025 Australian of the Year Awards and was named South Australia’s top performing mid-career researcher.